Stem Holdings, Inc.

Stem Holdings, Inc.

STMH
Stem Holdings, Inc.US flagOther OTC
0.00
USD
- -
- -
667.00Market Cap
Stem Holdings, Inc.
STMH
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
- -
3.69
15.6
8.68
23.23
13.14
- -
- -
- -
Revenue per Share
-0.99
-31.05
-104.73
-101.23
-18.29
-40.4
-7.68
-7.51
-7.78
Basic EPS, GAAP
-1.01
-47.05
-82.42
-28.05
-9.14
-6.3
-2.28
-0.49
-0.52
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
0.01
Dividend per Share
-0.94
-31.97
-138.74
-142.79
-85.33
-72.51
-58.86
-60.09
-62.26
Book Value per Share
22.58
47.31
99.78
57.38
10.54
5.24
3.32
-0.25
-0.26
Tangible Book Value per Share
- -
- -
- -
- -
1
2
2
3
2
Basic Weighted Avg Shares
- -
- -
1
2
14
21
- -
- -
- -
Sales/Revenue/Turnover
- -
-752.61
-647.92
-765.89
-69.17
-54.34
- -
- -
- -
Operating Margin (%)
- -
- -
1
1
2
2
2
- -
1
Depreciation Expense
- -
-3
-9
-29
-11
-64
-17
-19
-19
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-842.43
-671.14
-1,166.63
-78.73
-307.42
- -
- -
- -
Profit Margin (%)
2
- -
-3
-3
-9
5
17
-1
-1
Working Capital
- -
- -
2
- -
4
7
8
- -
- -
LT Debt
2
4
8
24
27
34
17
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
12.07
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
4
3
2
LT Borrowings
1
1
- -
LT Finance Leases
6
8
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
3
3
Market Capitalization
1
1
1

Working Capital

FRC

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
3
4
13
Cash, Cash Equivalents & STI
1
2
1
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
- -
Total Current Liabilities
7
6
14
Payables & Accruals
3
3
1
ST Debt
4
3
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
14.42%
-103.7%
Free Cash Flow
- -
-11.4%
-76.08%
Net Income, GAAP
- -
117.74%
9.5%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
5
5
5
9
21
2022
4
4
4
4
- -
2023
4
4
4
-12
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-4.58
-6.25
1.28
- -
-40.4
2022
-1.77
-1.55
0.24
- -
-7.68
2023
-1.34
-1.33
-0.43
- -
-7.51

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
0.01
- -
- -
- -
- -
Business
Stem Holdings, Inc. (STMH) operates with no significant current operations, having previously functioned as a vertically integrated cannabis branded products and technology company focused on cultivation, processing, extraction, retail, distribution, and delivery-as-a-service of cannabis and cannabis-infused products. Its former core offerings included award-winning brands such as TJ’s Gardens, TravisxJames, and Yerba Buena for flower and extracts; Cannavor (also referenced as Cannavore) edible confections; and proprietary e-commerce platforms like Budee and Ganjarunner providing direct-to-consumer logistics with omnichannel user experience. The company, founded in 2016 and headquartered in Boca Raton, Florida, targeted medical and recreational cannabis consumers primarily in the United States, with operations spanning states including California, Oregon, Nevada, and historically others aligned with state regulations. Recent developments include delays in annual filings leading to an expected cease trade order in January 2024, a proposed reverse merger with Headwaters, LLC announced in early 2023 that did not materialize, and a shift away from active cannabis activities, resulting in minimal revenue and ongoing financial challenges as of 2025.

Company News

APIChatGPT
  • CSE Bulletin: Delist - Stem Holdings Inc. (STEM)

  • Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

  • Cell Culture Market to Reach USD 44,593.1 million by 2034 amid Growing Demand for Biopharmaceuticals and Advances in Stem Cell Culture Techniques | Future Market Insights, Inc.

  • Naples Soap Company to Integrate Revolutionary NASA Stem Cell Technology into its New Skincare Line

  • Automotive Valve Stem Seal Market Valuation to Reach USD 866.5 Million by 2034, Driven by Continued Growth in Automotive Industry and Technological Advancements | Future Market Insights Inc.

  • Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)

  • City of Hope Awarded $5.4 Million CIRM Grant to Create a Stem Cell Laboratory and Expand Access to State-of-the-Art Disease Models and Technology Among a Diverse Scientific Community

  • CSE Bulletin: Suspension - Stem Holdings Inc. (STEM)

  • CSE Bulletin: Consolidation - Stem Holdings Inc. (STEM)

  • Stem Holdings, Inc. Announces Clarification Regarding Effective Date of Reverse Share Split on the Canadian Securities Exchange

  • Stem Holdings, Inc. Announces Effectiveness of Reverse Stock Split on February 1, 2024.

  • Stem Holdings Announces Delay in Annual Filings and Expected Cease Trade Order

  • Stem Holdings Announces Approval of Debenture Repricing

  • SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of Stem, Inc. (STEM) and Encourages Long-Term STEM Investors to Contact the Firm

  • Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Stem, Inc. f/k/a Star Peak Energy Transition Corp. (STEM)

  • Stem Holdings Sees Cannabis Earnings Rise, Aims For Positive Adjusted EBITDA in 2022

  • Budee™ Unveils New Shoppable Cannabis Delivery App for Apple

  • Driven By Stem Expands California E-Commerce and Delivery Footprint with New Distribution Hub License

  • Driven By Stem Announces the Acquisition of Artifact Extracts, Salem Delivery Capabilities, and Two Additional Dispensaries

  • Stem Holdings, Inc. (STMH) CEO Adam Berk on Q3 2021 Results - Earnings Call Transcript